Viatar CTC Solutions Announces $4.2 Million Series B

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Viatar CTC Solutions Announces $4.2 Million Series B Financing

LOWELL, MA--(Marketwired - Mar 1, 2016) - Viatar CTC Solutions, Inc. ( OTCQB : VRTT ), the cancer dialysis company, today announced that it has entered into agreements with existing shareholders for the sale of $4.2 million of Series B Preferred Stock. This transaction post-deal values Viatar at approximately $60 million, and is scheduled to be funded later in March 2016.

Viatar also reported its financial results for the fiscal year ended December 31, 2015.

The details of the Series B Convertible Preferred stock are as follows:

  • Stated value, liquidation value and conversion price are all at $2.50 per share.
  • The Series B shares are convertible at any time into common stock. The aggregate of approximately 1.7 million shares being sold will be convertible at any time into approximately 1.7 million shares of Viatar common stock, which is equal to 8.4% of the 20.3 million shares of common stock currently outstanding (on an as-converted basis with respect to these 1.7 million shares).
  • The dividend rate has been set at 9.5% annually, which accrues and is payable quarterly in additional shares of Series B preferred stock.
  • The dividend rate will increase to 12% in the event that by March 31, 2018 Viatar does not obtain CE Mark approval of its Therapeutic Oncopheresis System and generate at least $600,000 of gross profit in two fiscal quarters, subject to certain conditions.
  • Beginning in 2022, the Series B preferred stock will automatically convert into common stock at $2.50 per share, assuming Viatar's common stock then trades at or above $4 per share for 20 trading days with an average daily volume of 25,000 shares.

Mr. Ilan Reich, Viatar's Chairman and CEO, noted: "We project that the Series B financing will provide the funding needed to obtain CE Mark approval so that Viatar can begin commercialization of its Therapeutic Oncopheresis System in 2017 in Europe and Canada. This massive effort includes start-up manufacturing, clinical trial and regulatory compliance work. Much of this work will also support the FDA approval process, which we are pursuing on a parallel track."

"The Series B financing gives Viatar a post-deal valuation of roughly $60 million," Mr. Reich continued. "Obviously this is three times greater than Viatar's market capitalization since we became a public company in 2015. The contrast between the public and private market perceptions of Viatar's value is quite striking. In the past year Viatar has privately raised over $6 million in debt and preferred stock convertible at $2.50 per share, while on the OTCQB our stock has cumulatively traded only 130,000 shares at an average price of $1.03! I believe that given Viatar's proximity to regulatory approval and commercialization -- when medical device companies typically command valuations of $150 million to $250 million -- the valuation ascribed to Viatar in those private financings is both appropriate and advantageous to all parties."

Mr. Reich concluded: "I am also pleased to report that the Series B financing contains none of the death-spiral adjustments and deep discounts which are typically found in financings for microcap companies. It is a significant challenge to obtain the new capital necessary as a company matures from development stage to commercialization, and too often the cost is huge dilution borne by early investors, which is definitely not the case here."

Viatar also announced financial results for the full year of 2015. Viatar reported sales of $65,910 compared to $9,000 in 2014. Sales were higher in the second half of the year as the Company's filters were integrated into a customer's product line for use by medical researchers at prominent cancer institutions. Gross profit was $50,240, or 76% of revenue, for the full year of 2015.

Research & development expenses during 2015 were $2,475,906 compared to $1,305,159 in 2014. The largest component of the increase in 2015 of $938,978 was due to non-cash expenses for stock based compensation compared to $476,610 for the year ended December 31, 2014. The balance of the increase was due to higher staffing levels, use of third party engineering resources, and the purchase of supplies and equipment to support the oncology program as well as the first payment to an overseas hospital that has agreed to conduct a pilot human clinical trial.

General and administrative expenses during the twelve months of 2015 were $1,526,436, below the $2,080,936 recorded in 2014. The decrease was due to the significant financial advisory and legal expenses incurred during the year ended December 31, 2014 in order to become a public company.

Viatar reported a net loss of $4,066,286 for 2015 compared to a net loss of $4,199,630 for 2014. These losses include non-cash expenses of $938,978 and $476,610, for 2015 and 2014 respectively, for stock-based compensation.

At December 31, 2015, Viatar had cash assets of $508,445 and marketable securities of $480,000.

"Viatar made great progress in 2015," said Mr. Reich. "During the year we began to record commercial sales for our filtration technology; established key collaborations with researchers at major US cancer centers; and began the manufacturing, clinical trial and regulatory compliance tasks necessary to obtain CE Mark and FDA approval for our Therapeutic Oncopheresis System. We have a superb team of 25 employees and outside engineers working tirelessly on these programs."

Additional information on the new Series B preferred stock and financing can be found in the Company's Form 8K being filed today. Later this month Viatar will file its Form 10K for 2015, which will include audited financial statements.

The Series B preferred stock sold by Viatar in the private placement were not registered under the Securities Act of 1933, as amended (the "Securities Act"), and were sold in reliance upon exemptions from the registration requirements of the Securities Act. Such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws. This press release does not constitute an offer to sell any securities or a solicitation of an offer to purchase any securities.

About Viatar CTC Solutions

Viatar CTC Solutions Inc., the cancer dialysis company, is a medical technology company focused on the treatment of patients with metastatic cancer. The company's lead product, the Viatar™ Therapeutic Oncopheresis System , removes circulating tumor cells from whole blood using label-free cross-flow filtration. Pending regulatory approval targeted for 2017, it will be used as a periodic therapy to improve overall survival for a wide range of solid tumor types such as lung, breast, colon, prostate and gastric cancers. This proprietary technology also powers the company's liquid biopsy products, which are collection systems for use by genetic testing companies, researchers and medical oncologists that provide a greater quantity and purity of circulating tumor cells for their molecular analysis and personalized medicine objectives.

Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC.

   
Viatar CTC Solutions Inc. and Subsidiary  
Condensed Consolidated Statements of Operations  
(Unaudited)  
           
           
  For the Year Ended December 31,  
  2015     2014  
               
REVENUE              
  Sales $ 65,910     $ 9,000  
               
COST OF REVENUE              
  Cost of sales   15,670       -  
               
GROSS MARGIN   50,240       9,000  
               
EXPENSES              
  Research and development   2,475,907       1,305,159  
  General and administrative   1,526,436       2,080,936  
               
TOTAL EXPENSES   4,002,343       3,386,095  
               
LOSS FROM OPERATIONS   (3,952,103 )     (3,377,095 )
               
OTHER INCOME (EXPENSE)              
  Change in value of derivative liability   -       1,800  
  Interest expense   (114,183 )     (91,785 )
               
TOTAL OTHER INCOME (EXPENSE)   (114,183 )     (89,985 )
               
LOSS BEFORE INCOME TAX (EXPENSE) BENEFIT   (4,066,286 )     (3,467,080 )
               
  Income tax (expense) benefit   -       (732,550 )
               
NET LOSS   (4,066,286 )     (4,199,630 )
               
  Net loss attributable to noncontrolling interest in consolidated subsidiary   (548 )     (311 )
               
NET LOSS ATTRIBUTABLE TO STOCKHOLDERS $ (4,065,738 )   $ (4,199,319 )
               
LOSS PER COMMON SHARE - BASIC AND DILUTED:              
  Net Loss Attributable to Common Stockholders $ (0.23 )   $ (0.26 )
  Weighted Average Shares   17,796,745       15,853,810  
               

For More Information: For Viatar CTC Solutions: Ilan Reich Chairman & CEO ilan.reich@viatarctcsolutions.com Investor Contacts: Stephanie Prince PCG Advisory Group 646.762.4518 Sprince@pcgadvisory.com Dave Gentry RedChip Companies 407-644-4256, ext. 104 dave@redchip.com Media Contact: Sean Leous PCG Advisory Group 646.863.8998 sleous@pcgadvisory.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 110

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 125

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Roof Leaks Demand Diagnosis Before the Repair Bill

Updated Category News Views 35

A brown ring on a ceiling is often the last witness, not the crime scene. That is the useful, unglamorous point in Jonathan Floyd's HelloNation discussion of roof leaks: water has plenty of ways to move after it slips past a roof's defenses. Homeowners understandably stare at the stain and assume the answer sits directly overhead. Sometimes it does. Plenty of times, it...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 32

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 90

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 78

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 263

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 92

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Leatt Sets Its Virtual 2026 Shareholder Meeting Date

Updated Category News Views 38

A calendar notice is not a catalyst, but ignoring the calendar is how shareholders miss the small moments that matter. Leatt Corporation has scheduled its 2026 virtual annual general meeting of stockholders for Friday, November 20, at 11:00 AM Eastern Time. For holders of OTCQB:LEAT, this is a basic corporate-governance event, not a new product launch or a financial...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 33

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading

Top 5 Most Recently Viewed Articles

Dragonfly Energy Raises $25 Million Through Stock Offering

Updated Category News Views 255

Dragonfly Energy Secures $25 Million in Stock Offering RENO, Nev. — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (NASDAQ: DFLI), a leader in battery technology and energy storage solutions, has recently completed a significant underwritten offering. The offering involved issuing 20 million shares of common stock at a price of $1.25 each,...

Continue Reading
Exploring Cultural Ties: Tang Dynasty Exhibition Launch in Paris

Updated Category News Views 372

Celebrating Cultural Heritage Through the Tang Dynasty Exhibition The Tang Dynasty exhibition, titled "Tang China - A Cosmopolitan Dynasty (7th-10th Century)," has opened at the Guimet National Museum of Asian Arts, showcasing the rich history and cultural exchanges between China and France. The exhibition was celebrated by both Chinese President Xi Jinping and French...

Continue Reading
Leadership Changes at LP Building Solutions Enhance Board Experience

Updated Category News Views 250

Strategic Appointments at LP Building Solutions LP Building Solutions has made significant strides in enhancing its leadership structure by appointing Jean-Michel Ribiéras and Ty R. Silberhorn to its Board of Directors. This decision marks an important step for the company, which is recognized as a leading manufacturer in high-performance building products. As the...

Continue Reading
Chibougamau Independent Mines: Advancements in Mont Sorcier

Updated Category News Views 144

Mont Sorcier Project Continues to Advance Chibougamau Independent Mines Inc. is excited to share updates regarding the Mont Sorcier high-purity iron deposit. This project holds a significant position in the mining sector as Chibougamau retains a two percent Gross Metal royalty on the deposit. Recently, the company reported notable advancements in drilling and resource...

Continue Reading
Red Rock Resorts: Strong Performance in Q3 2025 Financials

Updated Category News Views 253

Red Rock Resorts Reports Impressive Q3 2025 Financial Results Red Rock Resorts, Inc. (NASDAQ: RRR) has announced its robust financial results for the third quarter, reflecting a substantial performance in various operational segments. These results point to a growing footprint in the gaming and hospitality industry, emphasizing the Company’s strong market position in...

Continue Reading